InternationalUSRemember you can easily switch between MIP US and MIP International at any time

Canada and Americas supplements now online

Michael Loney

Our latest supplements, on Canada and the Americas, are now available to read online. They include articles on Canada’s new drug and biosimilar patent linkage system and litigation landscape, Brazil’s new Civil Procedure Code, and Mexico’s boundaries of patent claim amendment

Managing IP has just published our latest supplements, focusing on Canada and the Americas.

The Canada supplement includes  an article on the country’s new drug and biosimilar patent linkage system. Bradley White and Nathaniel Lipkus of Osler Hoskin & Harcourt reveal it will fundamentally change the nature of proceedings.

The supplement also has an article on the landscape for IP litigation. Kevin Siu and Steven Garland of Smart & Biggar outline the benefits for global rights owners.

Managing IP also analysed the five most important decisions in Canada so far this year, including two from the Supreme Court and three from the Federal Court.

The Americas supplement includes an article on Brazil’s new Civil Procedure Code, which came into force last year. Breno Akherman and André Oliveira of Daniel Legal & IP Strategy analyse its impact on IP litigation so far.

The supplement also features an article exploring the boundaries of patent claim amendment in Mexico. Víctor Garrido of Dumont Bergman Bider & Co argue that clarity is needed on certain aspects of the law regarding patent claim amendment.

Managing IP has also this year published supplements on Asia-Pacific, Europe, China and Turkey. You can view them all here.



Managing IP


ManagingIP profile

RT @UPCtracker: This is one of nine (9) cases allocated to Justice Prof Huber (among them consolidated complaint re: adequate legal protect…

Feb 21 2018 05:15 ·  reply ·  retweet ·  favourite
ManagingIP profile

The complaint against the legislation enabling Germany to ratify the Agreement on a Unified Patent Court is includ…

Feb 21 2018 05:15 ·  reply ·  retweet ·  favourite
ManagingIP profile

Pfizer argued that plausibility should be an "evidential tool" not a "threshold test", while Actavis warned against…

Feb 21 2018 05:09 ·  reply ·  retweet ·  favourite

Popular Posts

Blog Archive

IP-related blogs

1709 Copyright Blog


AIA blog

Art and Artifice

China IPR

Class 99

Domain Incite

FOSS Patents

Green Patent Blog


IP CloseUp

IP Dragon

IP finance

IP Kat

IP Komodo

IP tango

IP Watchdog


MARQUES Class 46

Orange Book Blog

Patent Baristas



SPC Blog

Spicy IP

The Trademark Blog

The TTABlog